Share this article
Share this article
BAINBRIDGE ISLAND, Wash., April 23, 2021 /PRNewswire/ For two years, anticipation has been building among chefs, bakers, foodies, nutrition influencers, and even physicians about Big Bold Health®, a natural products start-up founded by Jeffrey Bland, PhD. The excitement is focused on a new type of flour that is milled from Himalayan Tartary Buckwheat, a plant with a remarkable nutrient profile that differs significantly from more common and widely available forms of buckwheat.
Himalayan Tartary Buckwheat as its name implies has an origin story that tracks to the rugged mountainous terrain of southeast Asia. Use of the plant as both a staple crop and a medicinal food dates back centuries in that region of the world. While academic researchers have made note of the potential health-promoting benefits of Himalayan Tartary Buckwheat s bioactive constituents in recent years, it was Dr. Bland a highly respected thought leader in the professional
Share
Bold Health, a London-based company developing digital therapeutics for gastrointestinal conditions, is backing a new University of Pennsylvania-led study that will directly compare the company s cognitive behavior therapy (CBT) app for irritable bowel syndrome (IBS) to Headspace s consumer mindfulness and meditation app.
According to a clinicaltrials.gov listing spotted by Exits & Outcomes, researchers will be randomly assigning 300 participants with IBS to receive either Bold Health s Zemedy app or the Headspace mindfulness app for free. Each group will have the app for eight weeks, after which those who received the Headspace app will also be given access to Zemedy.
At baseline and after those eight weeks, the researchers will administer a battery of questionnaires, and those who switched from Headspace to Zemedy will receive a third slew of questions after an additional eight weeks with Bold Health s app. Finally, participants in both groups will be contacted three m